Evidence map›Paper›PMID 42693134›Full record

ArticleNature communications2026

MBNL depletion drives stem cell fusion and immature myonuclear states in myotonic dystrophy type 1.

Vanessa Todorow, Xavière Lornage, Shinichiro Hayashi, Fiorella Carla Grandi, Zoé Clerc, Jeanne Lainé, Michel Ney, Mégane Lemaitre, Corentin Rouxel, Maria Kondili and 12 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Vanessa Todorow *Friedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.
Xavière Lornage *Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Shinichiro Hayashi *Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan. shinhayashi@ncnp.go.jp.ORCID http://orcid.org/0000-0001-5553-7698
Fiorella Carla GrandiSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.ORCID http://orcid.org/0000-0002-1303-6710
Zoé ClercSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Jeanne LainéSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Michel NeySorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.ORCID http://orcid.org/0000-0002-7214-7744
Mégane LemaitreSorbonne Université, Inserm, Phénotypage du Petit Animal, Paris, France.
Corentin RouxelSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Maria KondiliSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Piera SmeriglioSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Hanseul OhFriedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0002-4601-6951
Mie KatoDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Nobuyuki EuraDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID http://orcid.org/0000-0002-4943-3152
Yoshihiko SaitoDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID http://orcid.org/0000-0003-1643-4797
Francia Victoria A De Los ReyesDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
Satoru NoguchiDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID http://orcid.org/0000-0001-6165-3716
Benedikt SchoserFriedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany. benedikt.schoser@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-2757-8131
Denis FurlingSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France. denis.furling@sorbonne-universite.fr.ORCID http://orcid.org/0000-0001-7912-4409
Ichizo NishinoDepartment of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9452-112X
Peter MeinkeFriedrich-Baur-Institute at the Department of Neurology, LMU University Hospital, LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany.ORCID http://orcid.org/0000-0003-3359-3837
Frédérique RauSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myotonic dystrophy type 1 is caused by the expression of expanded CTG repeats in the DMPK gene and the resulting loss of function of MBNL protein. Affected skeletal muscle displays abundant centrally located nuclei despite limited immune-cell-associated fibre necrosis, complicating interpretation of muscle damage and remodelling mechanisms. Here we show that muscle stem cells are activated and fuse with existing muscle fibres in myotonic dystrophy type 1. Single-nucleus transcriptomics in patient's muscle identifies increased activated muscle stem cells and distinct myonuclear populations exhibiting transitional transcriptional states, including muscle stem cell associated markers and elevated DMPK expression. Myofibre-specific MBNL knockdown mouse models demonstrate that muscle stem cell fusion contributes to central nucleation, whereas their deletion does not improve myotonia or muscle strength. Together, these findings indicate that loss of MBNL function in muscle drives myonuclear accretion through stem cell-mediated fusion, giving rise to myonuclei with immature states in myotonic dystrophy type 1.

Indexed as

Myotonic DystrophyRNA-Binding ProteinsStem CellsAnimalsCell FusionCell NucleusDisease Models, AnimalDNA-Binding ProteinsFemaleHumansMaleMiceMuscle Fibers, SkeletalMuscle, SkeletalMyotonin-Protein KinaseDMPK protein, humanDMPK protein, mouseDNA-Binding ProteinsMBNL1 protein, humanMbnl1 protein, mouseMyotonin-Protein KinaseRNA-Binding Proteins

Identifiers

PMID42693134
PMCPMC13542076

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.